Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Translated title of the contribution: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

A.M.M. Eggermont, S. Suciu, R. MacKie, W. Ruka, A. Testori, W. Kruit, C.J Punt, M. Delauney, F. Sales, G. Groenewegen, D.J. Ruiter, I. Jagiello, K. Stoitchkov, U. Keilholz, Group EORTC Melanoma, D. Lienard

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPost-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Original languageUndefined/Unknown
Pages (from-to)1189-1196
Number of pages8
JournalThe Lancet
Volume366
DOIs
Publication statusPublished - 2005

Cite this